We Are the Frontier

New Platform Screens Drugs for Protein Interactions

The FIND tool identifies molecules that change how proteins interact, with further development needed before drug discovery potential is realized.

Updated on Nov. 5, 2026 in Biotech

New Platform Screens Drugs for Protein Interactions

Researchers at Harvard and Boston Children's Hospital have developed a high-throughput drug screening platform called FIND, which identifies molecules that change how proteins interact. A study demonstrating the platform was published in Science on November 5, 2026, and the research remains at the research stage rather than being an available product.

Why it matters

Most drug screens test whether a molecule binds a single target, while FIND looks at whether a molecule alters a protein-protein interaction, a category that has been harder to search at scale. The technology was licensed to a newly formed startup co-founded by members of the research team, signaling a move from academic lab to commercial development.

The study's evidence is a Science publication describing screens of a 400 million compound library against PPAR-gamma, with FIND identifying candidates that promote PPAR's binding to a fragment of CBP and a nanobody that modulates the SARS-CoV-2 spike protein and its receptor on human cells. The source does not report comparative benchmark figures against existing screening methods, and whether the hits translate into therapeutic effects is not yet established.

The players

Harvard

A research university whose researchers developed the FIND screening platform.

Boston Children's Hospital

A pediatric hospital that co-developed the FIND platform with Harvard researchers.

The details

FIND uses DNA nanoswitches, which are short DNA strands that change shape when proteins attach to them. When two attached proteins bind, the DNA strand forms a loop that identifies the protein pair by its encoded barcode. Each candidate stays linked to the result of its own experiment, and nanoswitches are separated by response and sequenced to identify selected molecules. The platform builds on DNA nanoswitch technology originally developed by Wong's research group.

Timeline

  1. Study demonstrating FIND published in Science on November 5, 2026.

The Tech Race

FIND extends the DNA nanoswitch technology first developed by Wong's research group into a drug screening tool aimed at protein-protein interactions. The work positions Harvard and Boston Children's Hospital in a field of platforms seeking to make this interaction class more searchable.

The FIND platform remains at the research stage, and no availability or pricing has been announced for patients or clinicians. Any eventual benefit depends on further development turning identified molecules into medicines, a timeline the source does not specify.

The takeaway

The key trajectory is whether FIND's approach to screening protein interactions yields drug candidates that advance beyond the lab. Watch for the startup's next development milestones and any follow-on studies testing the identified PPAR-gamma and nanobody compounds.

Further reading

Explore more Biotech developments shaping how new medicines are found.

Source note: This article includes information reported by Inside Precision Medicine.